Biofrontera AG
Biofrontera AG (BFFTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bfftf · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biofrontera AGYou BFFTF | $19M | N/A | — | — |
 Antisense Therapeutics Limited ATHJF | $20M | N/A | — | -$0.01 |
 TPCO Holding Corp. GRAMF | $20M | N/A | — | -$2.32 |
 The Hempshire Group, Inc. HMPSF | $16M | N/A | — | -$0.10 |
 Lifeist Wellness Inc. NXTTF | $16M | N/A | — | — |
 PharmChem, Inc. PCHM | $22M | 10.30x | — | $0.30 |
 RAMM Pharma Corp. RAMMF | $15M | N/A | — | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biofrontera AG (BFFTF) measures how much investors pay for each dollar of the company's trailing earnings. BFFTF's current PE ratio of N/A is calculated by dividing its stock price of $0.33 by its TTM earnings per share of —.
Frequently asked questions
BFFTF pe ratio · 6 questionsBFFTF's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.33 and TTM EPS of —. Data sourced from Financial Modeling Prep via BFFTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biofrontera AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10